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ABSTRACT
Objective This study analysed the analgesic effect and
changes in vital signs associated with administration of
inhaled Methoxyflurane (MTX) and/or intranasal Fentanyl
(INF) for prehospital management of visceral pain.
Method A retrospective, observational study reviewing
1024 randomly selected records of patients with
presumed visceral pain administered MTX (465), INF
(397) or both (162) by the Western Australian
Ambulance Service between January 2004 and February
2006. Clinical variables assessed included systolic blood
pressure, pulse rate, respiration rate and Glasgow Coma
Scale score. Pain was assessed utilising Visual/Verbal
Analogue Scale pain scores.
Results Overall effects on vital signs appeared
favourable 5 min after use and at hospital arrival with
either agent alone or in combination. As sole agents,
MTX produced the greatest initial pain scores reduction
(2.0 (1.7 to 2.2) vs 1.6 (1.4 to 1.8)) (mean (95% CI), and
INF provided greater pain reduction by hospital arrival
(3.2 (2.9 to 3.5) vs 2.5 (2.1 to 2.9)). While both agents
were effective, INF provided a greater pain score
reduction for cardiac (3.0 (2.6 to 3.4) vs 2.3 (1.8 to 2.8)),
female (3.4 (2.9 to 4.0) v 2.5 (2.0 to 3.0)) and age 75+
patients (3.2 (2.5 to 3.8) vs 1.8 (1.0 to 2.5)). Combined
use of agents was not advantageous.
Conclusions MTX and INF are effective agents for
providing visceral pain analgesia in the prehospital
setting. While MTX provided a more rapid onset of pain
relief, INF provided superior analgesia after subsequent
doses and in female, cardiac and older patients.

INTRODUCTION
A variety of prehospital analgesic agents have been
used by emergency care practitioners for many
years, but they share the common feature of
paucity of literature regarding safety, efﬁcacy and
relative efﬁciency.1
In Australia, the most frequently used analgesic
agent in ambulance practice is Methoxyﬂurane
(MTX), administered by First Aid, Volunteer and
Paramedic Ambulance personnel. Opioids are
authorised for use by all paramedics in some
services and selected ofﬁcers in others. In Western
Australia all paramedics are also authorised to
administer intranasal Fentanyl (INF) and its use is
increasing across ambulance services in Australia.
INF is becoming increasingly popular in paediatric
emergency medicine in Australasia in preference to
intravenous Morphine.2 3
Emerg Med J 2011;28:57e63. doi:10.1136/emj.2009.078717

Although these agents are well established in
local ambulance and military practice, they are not
widely used elsewhere in the world with few
reports regarding efﬁcacy and safety.4 5 The aim of
this study was to analyse the analgesic effect and
changes in vital signs associated with administration of MTX and INF in the prehospital management of pain of presumed visceral origin in Western
Australia, and to explore whether combined use is
advantageous.
MTX is a volatile, ﬂuorinated hydrocarbon used
for analgesia in paediatric and adult patients since
the 1960s.6 Reports have questioned its safety due
to dose-dependent nephrotoxicity for longer-term
analgesia7 and anaesthesia,8 particularly when used
in conjunction with known nephrotoxins.9 MTX
has been used routinely in subanaesthetic doses by
ambulance services Australia-wide for prehospital
analgesia for more than three decades at doses
lower than those reported above where adverse
events have been observed. The Therapeutic Goods
Administration (TGA) has no reports of renal
toxicity despite an estimated three million patient
treatments (Medical Developments International,
personal communication 2009). Small observational studies report it as a safe and reliable
prehospital analgesic when used at analgesic doses
for both adult10 and paediatric patients, with the
caveat that it may lead to brief, self-limiting
episodes of deep sedation in young children.11 12
Longer-term follow-up of more than 17 000
patients receiving MTX has shown no increase in
adverse events (I Jacobs, unpublished data 2009).
Exposure to anaesthetic gases is measured in
parts per million (ppm). Thresholds are described as
a time-weighted average (TWA) (the average
continuous exposure) and a ‘ceiling’ level over
a single hour, generally cited as four times the
TWA.13
Exposure Standards have not been established for
MTX. Standards for Halothane are accepted as
applicable and relevant. The TWA threshold for
Halothane as a sole agent (and hence MTX) is
50 ppm.14 However, in the operating room environment, Halothane is typically administered with
nitrous oxide (N2O) at 50 times the concentration
of Halothane. The TWA for N2O is 25 ppm. Hence,
in the operating room environment, the TWA for
Halothane is adjusted to 0.5 ppm (and ceiling value
2 ppm) because, although this is 100 times lower
than the threshold value for Halothane itself, a level
of Halothane of 0.5 ppm would be associated with
N2O at its threshold level of 25 ppm.
57
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An Ambulance commissioned study of MTX exposure found
that MTX levels did not reach the 1 h peak of 2 ppm or shift
average of 0.5 ppm unless oxygen was administered through the
device.15 Ambulance Services throughout Australia have now
changed Practice Guidelines to advise against routine administration of oxygen through the device (see online appendix).
Fentanyl is a potent, synthetic opioid used for analgesia since
the 1960s.16 Previous studies favourably report its safety and
efﬁcacy as a prehospital analgesic in both paediatric and adult
cases when administered intravenously17e22 or intranasally.3 23
Fentanyl has been suggested as the preferred opioid in the
prehospital setting19 due to its rapid pain relief, short duration of
action, non-histamine release (a major component contributing
to hypotension) and reduced incidence of nausea and
vomiting.16 21 24 When compared for efﬁcacy in the prehospital
setting, INF and intravenous morphine are comparable.23
Within the Western Australian Ambulance Service, the most
commonly used analgesic agents are inhaled MTX, introduced in
the 1980s and INF introduced in 2001. Combined use has been
reported by paramedics to enhance pain relief. This reported
synergism, however, remains to be veriﬁed.

METHODS
We undertook a retrospective, observational review of patient
care record forms encompassing patients administered MTX or
INF for the prehospital management of presumed visceral pain
by the Western Australian Ambulance Service between January
2004 and February 2006. For the purpose of this study, visceral
pain was determined by attending paramedics as being of
cardiac, renal or abdominal aetiology.
Of 14 232 cases available, 10 900 (76.6%) patients received
MTX, and 3332 (23.4%) patients received INF. Six hundred cases
were randomly selected per drug cohort, with cases coded as
abdominal, renal or cardiac pain. One thousand and twenty-four
cases had sufﬁcient data for further analysis. Of these, 465
(45.4%) received MTX, 397 (38.8%) received INF, and 162
(15.8%) received both.
MTX is self-administered by patients via a hand-held inhalation device (Penthrox inhaler; Medical Developments International, Springvale, Australia). A single dose of 3 ml delivers MTX
at a concentration of 0.2% or 0.4% depending on whether the
diluter hole is open or occluded. After an initial loading dose of
10e12 breaths through the device, the patient is encouraged to
take a few breaths through the device every few minutes as
required thereafter. A single dose will provide analgesia for
15e20 min if oxygen is administered through the device, or up
to 1 h if used intermittently (and oxygen administered separately by face mask as required). A second dose may be administered when the initial dose has been exhausted.
INF was administered by attending ambulance ofﬁcers via
a metered dose delivery at a concentration of 300 mg/ml in
accordance with the dosing regimen in table 1.
Table 1

Intranasal fentanyl dose regimen

Dose chart
Age

First dose

Subsequent at 10 min

<5 years <20 kg
6e10 years 21e30 kg

130.05 ml (15 mg)
130.10 ml (30 mg)

11e15 years 31e40 kg
Small/elderly/frail
Adult

130.15 ml (45 mg)
230.20 ml (120 mg)
330.20 ml (180 mg)

130.05 ml (15 mg)
130.10 ml (30 mg)
Subsequent at 5 min
130.15 ml (45 mg)
130.20 ml (60 mg)
130.20 ml (60 mg)

58

The choice of analgesic agent is at the discretion of the
attending paramedic. For both agents, administration is
continued as needed up to hospital arrival and may be continued
at the discretion of receiving hospital staff.
Data extracted from patient records included patient demographics (age, gender, aetiology of pain), vital signs (systolic
blood pressure (SBP), pulse rate, respiration rate and Glasgow
Coma Scale (GCS) score), and a pain assessment utilising Visual/
Verbal Analogue Scale (VAS) pain scores (assessed by paramedics). The limits used to deﬁne clinically signiﬁcant extremes
of vital sign measurements are listed in table 2. A 1.4-point
change in VAS pain score is considered clinically signiﬁcant.25 As
VAS pain scores for individual patients are assessed as whole
numbers, a change of 2 points was considered clinically signiﬁcant for an individual patient.

Statistics
Data were exported into and analysed with SPSS (version 11.5:
SPSS, Chicago, Illinois). Descriptive statistics and frequencies are
reported. A sample size of 600 per drug cohort was calculated to
provide 80% power to detect a statistical difference with a set at
0.05. A two-way, repeated-measures analysis of variance
(ANOVA) was used to test for signiﬁcant differences in vital sign
means over the measured intervals. The Student t test was used
to compare pain score reduction and c2 test for proportions with
pain score reduction $2 points.

RESULTS
Patient demographics
Males (584) represented 57% of the cohort, and most patients
(62.3%) were over 50 years of age with a mean age of 59.1
(female 58.7, male 59.4) years (table 3). Pain aetiology was
classiﬁed by the attending paramedic as cardiac (485, 47.4%),
abdominal (249, 24.3%) and renal (290, 28.3%) (table 4).

Physiological vital signs
SBP, pulse rate and respiration rate were recorded at three time
points: prior to administration of medication, 5 min after
administration and on arrival at hospital. Changes in conscious
state were assessed by determining GCS prior to and 5 min after
administration of the analgesic agent.

Blood pressure
Changes in SBP 5 min after initial analgesic dose varied considerably for individual patients (range 170 mm Hg to +70 mm
Hg). Despite these large individual variations, the majority of
changes were towards the normal range. Only four patients
with initial SBP>100 mm Hg entered the hypotensive range
(SBP<90 mm Hg). Three received INF as sole therapy for cardiac
pain, and one patient received both for abdominal pain.
The reduction in mean SBP 5 min after the initial dose of
MTX was 5.7 mm Hg (median 10 mm Hg) and after INF was
4.5 mm Hg (median 5 mm Hg) (table 5). Similar changes were
seen on arrival at hospital, with MTX reducing mean SBP by
15.1 mm Hg (median 20 mm Hg) and INF 11.5 mm Hg (median
15 mm Hg).
Table 2

Vital sign parameters classified as clinically significant

Vital sign

Lower limit

Upper limit

Systolic blood pressure (mm Hg)
Pulse rate (per min)
Respiration rate (per min)

<90 (hypotension)
<60 (bradycardia)
<8 (bradypnoea)

>180 (hypertension)
>100 (tachycardia)
>24 (tachypnoea)

Emerg Med J 2011;28:57e63. doi:10.1136/emj.2009.078717
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Table 3

Age group, gender and agent administered
Gender and agent

Age group (years)
0 to 29
30 to 44
45 to 59
60 to 74
75+
Unspecified
Grand total

Gender unspecified

Female

Fentanyl

Methoxy

Male
Fentanyl

Both

Female total

Methoxy
16
64
56
72
29
2
239

1
2

27
70
61
32
36

9
32
32
40
49

6
16
15
9
2

42
118
108
81
87

4

226

162

48

436

1

Fentanyl

Both

11
27
61
81
51

28
51
30
5

231

114

Male total

Grand total

27
119
168
183
85
2
584

69
238
276
265
174
2
1024

Analysis of the proportion of individual patients achieving
pain score reductions of two points or greater by hospital arrival
showed signiﬁcantly higher proportions with INF overall
(p¼0.027) and for the subgroups of cardiac aetiology (p¼0.033),
female patients (p¼0.021), female patients with cardiac aetiology (p¼0.044) and for patients aged 45e59 years (p¼0.047).
Further analysis of the patients aged 75+ years with cardiac
pain showed that the difference between agents was limited to
female patients in this subgroup (p¼0.003) where MTX
appeared to be ineffective (table 8).
Differences in pain score between agents were seen in the
age groups <30 years (1.50 reduction), 75+ years (1.41 reduction) and in the subgroup of patients with cardiac pain and aged
75+ years (males 1.16, females 1.99, overall 1.95).
The patient care records in use at the time of the study did not
record which agent was administered ﬁrst, and so this could not
be analysed. Combined use of agents was not advantageous.
For the 465 patients administered MTX, a single 3 ml dose
was used in 241 patients (51.9%), a second dose was used in 195
patients (41.9%) and 29 (6.2%) received a third dose. The mean
total dose of INF administered per patient was 362 mg (median
240 mg; SD6191.74).

On hospital arrival, 10 patients with initial SBP>100 mm Hg
had entered the hypotensive range. All received INF, nine with
cardiac and one abdominal pain. MTX was also administered to
the abdominal pain and two of the cardiac pain patients. None
of these patients received nitrates or other cardiac medications.
Of those who became hypotensive after treatment, no other
adverse effects in physiological parameters and no fall in GCS
were noted. One patient increased SBP within the hypertensive
range after treatment (SBP rise from 180 to 190 mm Hg).

Pulse rate
Pulse rate changes were minimal (table 5). In the majority of
cases, both agents affected pulse rate favourably towards normal
values, but changes were not signiﬁcant for either cohort.

Respiratory rate
Assessment of respiration indicated very little effect after
administration of either agent (table 5). Overall, mean respiration declined by 1.7 rpm initially and by 2.1 rpm on hospital
arrival, with median respiration rates unchanged. No patients
became bradypnoeic.

GCS
Changes in GCS were negligible (table 6). Five patients had falls
in GCS (maximum two points in a male with renal pain
receiving INF), and four patients had increased GCS (maximum
four points).

DISCUSSION
The objective of this study was to analyse and compare the
analgesic effect and changes in vital signs associated with
administration of MTX and/or INF for the prehospital
management of visceral pain. Both agents proved effective with
no bradypnoea.
Only one case increased SBP within the hypertensive range
(increase from 180 to 190 mm Hg) which is unlikely to be
clinically signiﬁcant. All cases that experienced a fall in SBP
from >100 mm Hg to hypotensive levels received INF either
alone or in combination with MTX. However, these patients did
not experience any fall in GCS or other evidence of respiratory or
cardiovascular compromise. The results concur with previous
studies indicating that INF is an agent with good analgesic
properties.2 26e28 While one small study found that the rate of
adverse events for patients treated with INF in a prehospital

Pain scores
Pain score reduction by VAS was assessed 5 min after treatment
and on arrival at hospital (table 7). A further subgroup analysis
by agent, gender, aetiology and pain group was also performed
(table 8). Transport times were comparable for both agents.
As sole agents, MTX produced the greatest initial pain score
reduction (p¼0.452), and INF provided greater pain reduction by
hospital arrival (p¼0.007). While both agents were effective, INF
provided a signiﬁcantly greater pain score reduction for cardiac
(p¼0.025), female (p¼0.020) and age 75+ patients (p¼0.006) on
arrival at hospital.
Table 4

Aetiology, gender and agent administered
Gender and agent
Gender unspecified

Female

Aetiology

Fentanyl

Methoxy

Fentanyl

Both

Female total

Methoxy

Fentanyl

Both

Male total

Grand total

Abdominal
Cardiac
Renal
Grand total

1
3

61
107
58
226

52
99
11
162

32
3
13
48

145
209
82
436

37
97
105
239

37
159
35
231

29
17
68
114

103
273
208
584

249
485
290
1024

4

Male

Emerg Med J 2011;28:57e63. doi:10.1136/emj.2009.078717
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133.1
(131.2 to 135.0)
18
822
68
82.8
(81.5 to 84.1)
62
715
172
20.5
(20.3 to 20.8)
0
730
201

Hospital
5 min
Initial

137.9
(136.0 to 139.7)
20
917
70
85.0
(83.7 to 86.4)
63
765
193
22.2
(21.9 to 22.5)
0
790
213
127.2
(122.2 to 132.3)
1
89
7
80.5
(77.6 to 83.4)
2
83
18
19.2
(18.6 to 19.8)
0
83
17
134.8
(130.2 to 139.5)
1
132
12
80.2
(77.6 to 82.7)
8
123
21
20.1
(19.6 to 20.6)
0
124
26
137.3
(132.8 to 141.9)
1
145
12
82.6
(79.9 to 85.4)
8
131
22
21.6
(20.9 to 22.2)
0
131
27
126.4
(123.3 to 129.5)
6
262
31
83.0
(80.3 to 85.6)
27
219
64
19.9
(19.5 to 20.4)
0
232
75
133.4
(130.2 to 136.5)
12
323
35
84.3
(81.9 to 86.7)
35
273
80
20.7
(20.2 to 21.1)
0
293
84
137.9
(134.6 to 141.2)
13
346
35
86.0
(83.5 to 88.5)
35
280
81
22.2
(21.7 to 22.8)
0
300
89
122.9
(119.4 to 126.3)
3
194
11
81.1
(78.7 to 83.6)
14
164
38
20.7
(20.1 to 21.3)
0
147
68
132.3
(129.6 to 135.0)
5
367
21
82.4
(80.6 to 84.2)
19
319
71
20.6
(20.2 to 21.0)
0
313
91
138.0
(135.3 to 140.6)
6
426
23
85.0
(83.4 to 86.7)
20
354
90
22.3
(21.8 to 22.8)
0
359
97
Average
(95% CI)
<90
90e180
>180
Pulse rate
Average
(per min)
(95% CI)
<60
60e100
>100
Respiratory rate Average
(per min)
(95% CI)
<12
12e24
>24
Systolic blood
pressure
(mm Hg)

Total

Hospital
5 min
Initial

Both

Hospital
Initial

5 min
Fentanyl

5 min

Hospital
Methoxy

Initial

Changes in physiological parameters by agent used
Table 5

setting was more than double that of patients administered
with intravenous morphine, these effects were minor and did
not reach statistical signiﬁcance.23
MTX as a sole agent was not associated with any adverse
physiological effects.
The results of the current study of prehospital MTX and INF
indicate both provide effective pain relief. MTX showed
a greater pain reduction 5 min after commencement of treatment. INF showed a superior pain reduction on arrival at
hospital. The results of this study concur with studies
conducted in a hospital environment, which report a mean
reduction in VAS pain score of approximately four points.29 30
The time course of VAS pain score reduction we observed is
similar to that in hospital for paediatric patients (1.67 point
reduction 10 min postadministration and 2.91 point reduction
30 min postadministration).31
The subgroup analysis shows that both agents provide effective analgesia across the range of age, gender and pain aetiology.
INF produced greater increases in pain score reduction and
proportion of patients with VAS reduction of two or more in the
subgroups of cardiac pain, female patients and age 75 years and
above on arrival at hospital.
It is reassuring to note that for cardiac aetiology of pain,
neither INF nor MTX caused respiratory depression or adverse
pulse rate changes. INF administration demonstrated more
effective pain relief in this group but was also associated with
a small number of cases developing hypotension. These
effects do not appear to have been associated with clinical
compromise and are reassuring in this particular group who are
at greatest risk of cardiovascular compromise from analgesic
agents.
This study has demonstrated similar results to that seen when
morphine was compared with the fentanyl derivative alfentanil
for relief of acute ischaemic-type chest pain in the prehospital
environment.32 More rapid pain relief from alfentanil was noted
15 min after administration. However, while INF provided
greater pain relief at arrival at hospital, it is evident that MTX is
also an effective analgesic agent. Further analysis of the cardiac
patients aged 75 years and above showed INF to be particularly
effective and MTX ineffective in this group. However, the actual
numbers are small, and caution is advised on interpretation of
this result.
Historical analysis of INF dosage administration by St John
Ambulance paramedics in Western Australia demonstrates
a substantial increase in dose per patient since its introduction in
2001, with the average administration increasing from 180 mg in
the initial stages following introduction of the agent (Ford D,
unpublished, 2004) to the mean reported here of 362 mg.
Following analysis of the pilot period in 2001, the initial dose for
adults was increased in 2002 from 120 mg to 180 mg, and ongoing
education has reinforced the need to continue administration at
the recommended intervals if pain relief is inadequate. Increased
experience and comfort with use have also contributed to this
increase in total dose per person observed over time. The
increased total dose administered per patient since initial use in
2001 to that observed here in 2004, without signiﬁcant adverse
effects, is most likely reﬂective of previously inadequate doses.
This ‘oligoanalgesia’ is well recognised in the prehospital
setting.33e35
It should be noted that as the population examined in this
study were suffering from visceral pain, they are therefore
physiologically distinct from patients with pain of traumatic
origin, which has been more extensively studied. This may
explain the difference between previous ﬁndings of a four-point

125.3
(123.2 to 127.4)
10
545
49
81.9
(80.3 to 83.5)
43
466
120
20.1
(19.7 to 20.4)
0
462
160

Prehospital care

Emerg Med J 2011;28:57e63. doi:10.1136/emj.2009.078717

Downloaded from emj.bmj.com on July 21, 2011 - Published by group.bmj.com

The limitations of the study are consistent with retrospective,
observational studies of this nature and relate to available
equipment, the study population and compliance with recording
procedures.
The investigation of the analgesic agents’ effect on respiration
has been limited to respiratory rate and GCS. More sensitive
indicators are oxygen saturation and end tidal CO2 (ETCO2)
monitoring. However, oxygen saturations were not routinely
measured and/or repeated at the time of this study and ETCO2
monitoring in spontaneously breathing patients requires
Emerg Med J 2011;28:57e63. doi:10.1136/emj.2009.078717

Initial

Total

6.3
(6.1 to 6.4)
1.8
(1.7 to 1.9)
8.1
(7.9 to 8.2)
5.4
(4.9 to 5.9)
3.4
(2.8 to 3.9)
7.0
(6.6 to 7.3)
1.8
(1.5 to 2.2)
8.8
(8.6 to 9.0)
4.4
(4.1 to 4.7)
3.2
(2.9 to 3.5)
6.0
(5.8 to 6.3)
1.6
(1.4 to 1.8)
7.6
(7.4 to 7.8)
5.5
(5.1 to 5.9)
2.5
(2.1 to 2.9)
Pain reduction

Limitations

6.2
(5.9 to 6.4)
2.0
(1.7 to 2.2)

pain reduction for traumatic pain (Ford, unpublished, 2004)
compared with a three-point reduction found in this study of
visceral pain.36e38
The use of MTX has changed since the time of this study.
Previously, it was routine practice to administer oxygen through
the device. This is now recognised to increase evaporation of the
agent into the ambient air, reducing the dose delivered to the
patient and limiting analgesia to 15e20 min. The current
recommended technique is to administer oxygen via a separate
face mask and not through the inhaler (see online appendix).
Intermittent use of MTX in this manner allows a single dose to
last approximately 1 h, and as a result, the need to reﬁll the
inhaler with a second dose is now exceedingly uncommon. The
briefer duration of effect with oxygen administered through the
devicedwhich was common at the time of the studydmay also
contribute to the lesser effect of MTX with longer transports
and by hospital arrival despite having a greater initial effect.
With oxygen ﬂowing through the device, exhaustion of the
MTX may not have been apparent to either patient or treating
ofﬁcer and hence analgesic effect removed. Further analysis with
the current technique and/or comparison of techniques may
yield more information.
Interestingly, there was no signiﬁcant difference in pain
assessment scores of patients who received MTX and INF in
combination, relative to INF alone. This is consistent with
a previous study23 that demonstrated similar or less pain
reduction when these agents were combined in patients with
non-cardiac pain. One possible explanation is that a second
agent has been used when the ﬁrst agent is ineffective, and
hence the use of both agents is apparently less as it is a group of
relative ‘non-responders’ or those suffering hyperalgesia. Further
studies will be required to examine the sequence and timing of
agents and the effect of each individually when used in combination. It is also unknown how frequently both agents were
used simultaneously from the outset. Until these issues are
clariﬁed, no ﬁrm recommendations can be made regarding
routine use of both agents.

8.1
(7.9 to 8.3)

1

Average
(95% CI)
Average
(95% CI)

1

Hospital

3
11

5 min

996

Both

1
156

Hospital

459
3
381
5
1
1
156
3
1009

5 min

1

Initial

Grand total

Fentanyl

11

Hospital

2
2
1
3

12

5 min

Grand total

456
1
380
2
1

13

Methoxy

Both

14

Initial

Fentanyl

15
14
15
14
13
12
15
14

15

Changes in pain scores by agent used

Methoxy

Glasgow Coma
Scale after agent

Table 7

Agent

5 min

Glasgow Coma
Scale before agent

Pain score

Hospital

Glasgow Coma Scale before and after treatment

Initial

Table 6

4.9
(4.7 to 5.2)
3.0
(2.8 to 3.2)

Prehospital care
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Table 8

Pain score reduction at hospital arrival: subgroup analysis of methoxyflurane and intranasal fentanyl use as sole agents

Gender

Group

No
Methoxy

All
All
All
175
AetiologyAll
Abdominal 37
All
Renal
27
All
Cardiac 111
Gender All
Male
76
All
Female
99
Abdominal 9
Gender Male
and
Male
Renal
15
aetiology
Male
Cardiac
52
Female
Abdominal 28
Female
Renal
12
Female
Cardiac
59
Age
All
0 to 29
15
group All
30 to 44 42
All
45 to 59 45
All
60 to 74 39
All
75+
33
10
Cardiac Male
75
Female
9
+ years
Unspecified
0
Total
19

Pain reduction on
arrival at hospital
No
Methoxy average
Fentanyl (95% CI)

Pain reduction on
arrival at hospital
Fentanyl average
(95% CI)

p Value*
Numerical
Pain reduction on Difference in
arrival at hospital pain reduction

2+
reduction
Methoxy
no (%)

273
50
23
200
167
102
26
18
123
23
5
74
10
36
64
96
67
25
25
2
52

3.18
3.81
3.24
3.02
3.06
3.40
3.52
3.47
2.91
3.96
2.40
3.30
4.30
3.85
2.76
3.11
3.17
3.36
3.32
1.50
3.27

0.007
0.120
0.337
0.025
0.108
0.020
0.413
0.849
0.113
0.178
0.505
0.066
0.058
0.206
0.233
0.505
0.006
0.139
0.003
NA
0.003

113 (65%) 203 (74%)
27 (73%) 42 (84%)
21 (78%) 20 (87%)
65 (59%) 141 (71%)
50 (66%) 121 (72%)
63 (64%) 80 (78%)
6 (67%) 21 (81%)
14 (93%) 16 (89%)
30 (58%) 84 (68%)
21 (75%) 20 (87%)
7 (58%)
4 (80%)
35 (59%) 56 (76%)
12 (80%) 10 (100%)
32 (76%) 32 (89%)
24 (53%) 46 (72%)
27 (69%) 68 (71%)
17 (52%) 47 (70%)
6 (60%) 17 (68%)
1 (11%) 17 (68%)
NA
1 (50%)
7 (37%) 35 (67%)

2.51
2.97
2.67
2.32
2.51
2.51
2.67
3.33
2.25
3.07
1.83
2.38
2.80
3.14
2.12
2.79
1.76
2.20
0.33
NA
1.32

(2.14 to 2.88)
(2.16 to 3.79)
(1.74 to 3.59)
(1.85 to 2.79)
(1.97 to 3.06)
(2.00 to 3.02)
(0.94 to 4.40)
(2.19 to 4.48)
(1.60 to 2.90)
(2.14 to 4.01)
(0.41 to 3.26)
(1.71 to 3.05)
(1.59 to 4.01)
(2.41 to 3.88)
(1.27 to 2.98)
(2.06 to 3.53)
(1.03 to 2.48)
(1.08 to 3.32)
(e0.84 to 1.51)
(0.42 to 2.22)

(2.87 to 3.50)
(3.16 to 4.46)
(2.54 to 3.94)
(2.63 to 3.41)
(2.68 to 3.45)
(2.86 to 3.95)
(2.56 to 4.48)
(2.63 to 4.31)
(2.44 to 3.37)
(3.10 to 4.81)
(1.62 to 3.18)
(2.60 to 3.99)
(3.47 to 5.13)
(3.05 to 4.64)
(2.17 to 3.35)
(2.53 to 3.70)
(2.52 to 3.82)
(2.39 to 4.33)
(1.97 to 4.67)
(e1.44 to 4.44)
(2.47 to 4.07)

0.67
0.84
0.57
0.70
0.55
0.89
0.85
0.14
0.66
0.89
0.57
0.92
1.50
0.70
0.64
0.32
1.41
1.16
1.99
NA
1.95

2+
reduction
Fentanyl
no (%)

p Valuey
2+
reduction
0.027
0.209
0.400
0.033
0.291
0.021
0.385
0.658
0.179
0.285
0.394
0.044
0.132
0.145
0.047
0.853
0.068
0.652
0.003
NA
0.021

*t Test.
yc2 Test.
NA, not applicable.

equipment not currently utilised in ambulance services in
Australia. It is possible, therefore, that minor degrees of respiratory depression have not been identiﬁed. Similarly, GCS is
a crude estimate of conscious status. Confusion and/or disorientation are important effects produced by both these agents
but not speciﬁcally analysed in this study. Further research is
required to assess the signiﬁcance or otherwise of these factors.
No allowance has been made for the analgesic effect of
nitrates and oxygen for patients with pain of presumed cardiac
origin. Although the use of these confounders is routine and is
assumed to be similar between subgroups, this was not speciﬁcally analysed. Similarly, the pathological conditions associated
with visceral pain inﬂuence the physiological parameters
measured making interpretation of changes difﬁcult to determine because of pain, pain relief, underlying condition or
combinations of these.
While the study population encompassed all age groups, only
1.1% of patients were under 20 years of age. Paediatric patients
are therefore under-represented in this study, and as such we are
unable to speciﬁcally analyse the effects in this group. Finally,
the analysis of patient records was hampered by incomplete
data, with missing values attributed to short journey time to
hospital and non-compliance with completion of the case sheets
by paramedics.

CONCLUSION
The results presented in this paper demonstrate MTX and INF
are effective analgesic agents for the prehospital management of
visceral pain, with only a very small number of cases in the INF
group associated with subsequent hypotension but no change in
GCS or other evidence of cardiovascular compromise. No
patients were compromised by a fall in consciousness level or
impaired respiratory rate. MTX may be the treatment of choice
for shorter patient contact cases due to ease of administration,
but INF provided superior pain relief at hospital arrival, and
62

achieved greater pain relief for presumed cardiac pain, particularly in older and female patients. No clinical advantage could be
detected by their combined use, however measures were limited.
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